Literature DB >> 14688470

Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer.

Hiroyuki Matsubayashi1, Noriyoshi Fukushima, Norihiro Sato, Kieran Brune, Marcia Canto, Charles J Yeo, Ralph H Hruban, Scott E Kern, Michael Goggins.   

Abstract

Long standing chronic pancreatitis is a risk factor for developing pancreatic cancer. Inheritance of polymorphisms in SPINK1 and CFTR are associated with an increased risk of developing pancreatitis. The aim of this study was to determine if patients who carry polymorphisms in SPINK1 and CFTR are at increased risk of developing pancreatic cancer through the development of chronic pancreatitis. DNA from patients with histologically-confirmed surgically-treated chronic pancreatitis, familial and sporadic pancreatic adenocarcinoma and controls were analyzed for the N34S polymorphism of SPINK1 and the two commonest polymorphisms of the CFTR gene, the DF508 mutation and the 5T polymorphism. These polymorphisms were determined using restriction fragment length polymorphism, PCR and cycle sequencing methods. The SPINK1 N34S polymorphism was detected in 5 of 172 (2.9%) patients with chronic pancreatitis, in 4 of 200 (2.0%) patients with sporadic pancreatic adenocarcinoma, in 0 of 36 (0%) of patients with familial pancreatic cancer and in 3 of 177 (1.7%) controls of chronic cholecystitis. The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer. The CFTR DF508 mutation was recognized in 6 of the 240 (2.5%) patients with pancreatic adenocarcinoma, a prevalence similar to that of control populations. We conclude that the N34S polymorphism of SPINK1 and the 5T and DF508 CFTR polymorphisms do not predispose to the development of pancreatic adenocarcinoma. Furthermore, the N34S polymorphism is rarely found in patients with severe idiopathic chronic pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688470

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma.

Authors:  R McWilliams; W E Highsmith; K G Rabe; M de Andrade; L A Tordsen; L M Holtegaard; G M Petersen
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

3.  Proteomic analysis of formalin-fixed paraffin-embedded pancreatic tissue using liquid chromatography tandem mass spectrometry.

Authors:  Joao A Paulo; Linda S Lee; Peter A Banks; Hanno Steen; Darwin L Conwell
Journal:  Pancreas       Date:  2012-03       Impact factor: 3.327

4.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma.

Authors:  Robert R McWilliams; Gloria M Petersen; Kari G Rabe; Leonard M Holtegaard; Pamela J Lynch; Michele D Bishop; W Edward Highsmith
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

Review 5.  Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature.

Authors:  David W Rittenhouse; Vanessa A Talbott; Zafia Anklesaria; Jonathan R Brody; Agneszkia K Witkiewicz; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2011-08-02       Impact factor: 3.452

6.  Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer.

Authors:  Koji Tamura; Jun Yu; Tatsuo Hata; Masaya Suenaga; Koji Shindo; Toshiya Abe; Anne MacGregor-Das; Michael Borges; Christopher L Wolfgang; Matthew J Weiss; Jin He; Marcia Irene Canto; Gloria M Petersen; Steven Gallinger; Sapna Syngal; Randall E Brand; Anil Rustgi; Sara H Olson; Elena Stoffel; Michele L Cote; George Zogopoulos; James B Potash; Fernando S Goes; Richard W McCombie; Peter P Zandi; Mehdi Pirooznia; Melissa Kramer; Jennifer Parla; James R Eshleman; Nicholas J Roberts; Ralph H Hruban; Alison Patricia Klein; Michael Goggins
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-18       Impact factor: 11.205

Review 7.  Early diagnosis of pancreatic cancer: challenges and new developments.

Authors:  Sukhwinder Kaur; Michael J Baine; Maneesh Jain; Aaron R Sasson; Surinder K Batra
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

Review 8.  Strategies for early detection of resectable pancreatic cancer.

Authors:  Keiichi Okano; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer.

Authors:  Gabriele Lami; Maria Rosa Biagini; Andrea Galli
Journal:  World J Gastrointest Endosc       Date:  2014-07-16

Review 10.  Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer.

Authors:  Jieting Zhang; Yan Wang; Xiaohua Jiang; Hsiao Chang Chan
Journal:  Cell Mol Life Sci       Date:  2018-02-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.